DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Elitek (Rasburicase) - Published Studies

 
 



Elitek Related Published Studies

Well-designed clinical trials related to Elitek (Rasburicase)

[Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome] [2010.02]

A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. [2009.11]

A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. [2009.04]

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. [2001.05.15]

Well-designed clinical trials possibly related to Elitek (Rasburicase)

Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. [2010.06.16]

Other research related to Elitek (Rasburicase)

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. [2012]

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. [2011.10.19]

A review of tumour lysis syndrome with targeted therapies and the role of rasburicase. [2011.06]

Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. [2011.06]

Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases. [2011.03]

Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia. [2011.02]

Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients. [2010.12.15]

Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. [2010.10]

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. [2010.09.20]

Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome. [2010.09]

Rasburicase improves hyperuricemia in infants with acute kidney injury. [2010.02]

A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. [2009.08.22]

[Rasburicase for tophaceus gout treatment] [2009.07]

Urate oxidase (rasburicase) for treatment of severe acute gout: a case report. [2009.07]

[A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase] [2009.07]

Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. [2009.04]

Efficacy of rasburicase in hyperuricemia secondary to Lesch-Nyhan syndrome. [2009.04]

Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. [2009.02]

Rasburicase: future directions in tumor lysis management. [2008.10]

[Rasburicase therapy may cause hydrogen peroxide shock] [2008.08.24]

Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. [2008.06]

Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. [2008.04]

Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase. [2008.04]

SFCE (Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey. [2008.04]

Rasburicase in the prevention and treatment of tumour lysis syndrome. [2008.02]

Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease. [2008]

[Efficacy of rasburicase therapy in obstructive renal failure secondary to urolithiasis: a novel therapeutic option] [2008]

Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. [2007.10]

Catalase deficiency may complicate urate oxidase (rasburicase) therapy. [2007.09]

Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study. [2007.05]

Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. [2007.03.02]

Clarifying the role of rasburicase in tumor lysis syndrome. [2007.01]

Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. [2007]

Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. [2006.09]

Rasburicase for the management of tumor lysis syndrome in neonates. [2006.07]

Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. [2006.06]

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. [2006.06]

Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. [2006.06]

Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea. [2006.04]

[Analysis and protocolization of rasburicase use in patients with hematologic neoplasms] [2006.03]

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. [2006.02]

Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy. [2006.01]

Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. [2006]

Spotlight on rasburicase in anticancer therapy-induced hyperuricemia. [2006]

Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia. [2006]

Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. [2005.12]

Hemolysis and methemoglobinemia secondary to rasburicase administration. [2005.11]

A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. [2005.04]

Managing malignancy-associated hyperuricemia with rasburicase. [2005.03]

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. [2005.01]

Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. [2005]

Rasburicase therapy in acute hyperuricemia and renal dysfunction. [2005]

Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. [2005]

Management of hyperuricemia with rasburicase review. [2004.10]

Stabilization of rasburicase and physico-chemical characterization of the resulting injectable formulation. [2004.09]

[Rasburicase (Fasturtec)] [2004.09]

Use of single-dose rasburicase in an obese female. [2004.09]

Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis. [2004.08]

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. [2003.12.01]

Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. [2003.11.01]

Treatment of impending tumor lysis with single-dose rasburicase. [2003.11]

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. [2003.09.01]

Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. [2003.08]

Rasburicase for the treatment and prevention of hyperuricemia. [2003.07]

Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. [2003.04]

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. [2003.03]

Rasburicase: a potent uricolytic agent. [2002.04]

Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome. [2002.01]

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. [2001.10]

Rasburicase. [2001]

Other possibly related research studies

Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. [2005.01]

Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. [2005]

Hyperuricemic syndromes in cancer patients. [2005]

Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. [2005]

Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. [2003.03]

Prevention and treatment of hyperuricemia in hematological malignancies. [2002.12]

Challenges in the management of Burkitt's lymphoma. [2002.12]

Gateways to clinical trials. [2005.09]

[Tumor lysis syndrome: risk factors and treatment] [2005.01]

Gateways to clinical trials. [2005.03]

Current management of gout in patients unresponsive or allergic to allopurinol. [2004.11]

Gateways to clinical trials. [2004.05]

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. [2004.04.15]

[Gout] [2004.02]

Gateways to clinical trials. [2003.09]

Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. [2003.12]

Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. [2003.05]

Acute tumor lysis syndrome in solid tumors--a case report and review of the literature. [2003.03]

Gateways to Clinical Trials. June 2002. [2002.06]

Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. [2001.10]

European experience in the treatment of hyperuricemia. [2001.10]

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. [2001.02.01]

Gateways to clinical trials. [2006.09]

Newer therapeutic approaches: gout. [2006.02]

Gateways to clinical trials. [2006.07]

The management of tumor lysis syndrome. [2006.08]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017